STOCK TITAN

EyePoint Pharmaceuticals Inc - EYPT STOCK NEWS

Welcome to our dedicated news page for EyePoint Pharmaceuticals (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EyePoint Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EyePoint Pharmaceuticals's position in the market.

Rhea-AI Summary
EyePoint Pharmaceuticals to report Q2 2023 financial results and highlight recent corporate developments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.9%
Tags
conferences earnings
-
Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced the granting of non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $10.97 per share, a ten-year term, and vest over four years. Vesting is subject to the employee’s continued service with EyePoint Pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) appoints Jay S. Duker, M.D. as the new President and CEO, with Nancy S. Lurker transitioning to Executive Vice Chair of the Board of Directors. Dr. Duker has been appointed to the Board of Directors, effective immediately. The company has achieved significant value-enhancing catalysts over the past years, including the advancement of EYPT-1901 into two Phase 2 trials and revenue growth for YUTIQ, culminating in a successful sale of commercial rights. EyePoint is now positioned as a pure play drug development company with a compelling clinical pipeline and recent financial and clinical achievements, strengthening its position in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.31%
Tags
none
-
Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. will present a company overview at the Jefferies Healthcare Conference on June 7, 2023. The presentation will be available via webcast and archived replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.73%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.48%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.01%
Tags
none
EyePoint Pharmaceuticals Inc

Nasdaq:EYPT

EYPT Rankings

EYPT Stock Data

1.12B
30.74M
1.02%
104.69%
13.74%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States
Watertown

About EYPT

psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®